These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16753443)

  • 21. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM; Frazier MC; Harris WB
    Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
    Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
    Mitterberger M; Neuwirt H; Cavarretta IT; Hobisch A; Culig Z
    Prostate; 2007 Aug; 67(11):1194-201. PubMed ID: 17520660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
    Pang B; Zhang H; Wang J; Chen WZ; Li SH; Shi QG; Liang RX; Xie BX; Wu RQ; Qian XL; Yu L; Li QM; Huang CF; Zhou JG
    Prostate; 2009 Aug; 69(11):1176-87. PubMed ID: 19415690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
    Hobisch A; Fiechtl M; Sandahl-Sorensen B; Godoy-Tundidor S; Artner-Dworzak E; Ramoner R; Bartsch G; Culig Z
    Prostate; 2004 Jun; 59(4):401-8. PubMed ID: 15065088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
    Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
    Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
    Thelen P; Wuttke W; Jarry H; Grzmil M; Ringert RH
    J Urol; 2004 May; 171(5):1934-8. PubMed ID: 15076315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
    Chen F; Knecht K; Leu C; Rutledge SJ; Scafonas A; Gambone C; Vogel R; Zhang H; Kasparcova V; Bai C; Harada S; Schmidt A; Reszka A; Freedman L
    J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):247-57. PubMed ID: 15336702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
    Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
    Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
    Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
    Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen receptor-mediated repression of novel target genes.
    Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
    Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells.
    Angelucci C; Iacopino F; Lama G; Capucci S; Zelano G; Boca M; Pistilli A; Sica G
    Anticancer Res; 2004; 24(5A):2729-38. PubMed ID: 15517879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
    Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase.
    Bai VU; Cifuentes E; Menon M; Barrack ER; Reddy GP
    J Cell Physiol; 2005 Aug; 204(2):381-7. PubMed ID: 15887248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
    Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M
    Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
    Abdelbaqi K; Lack N; Guns ET; Kotha L; Safe S; Sanderson JT
    Prostate; 2011 Sep; 71(13):1401-12. PubMed ID: 21321979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cells.
    Thelen P; Peter T; Hünermund A; Kaulfuss S; Seidlová-Wuttke D; Wuttke W; Ringert RH; Seseke F
    BJU Int; 2007 Jul; 100(1):199-203. PubMed ID: 17488304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
    Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.